Investing
GSK reports Blenrep outperforms in phase III multiple myeloma trial
© Reuters.
GSK has disclosed encouraging results from its phase III DREAMM-7 trial, revealing that Blenrep (belantamab mafodotin) has shown effectiveness as a second-line treatment for relapsed or refractory multiple myeloma. The trial, which compared Blenrep plus BorDex to daratumumab plus BorDex, involved 494 patients who had previously undergone therapy but experienced disease progression. The independent review recommended early unblinding due to promising interim outcomes, with Blenrep demonstrating a significant improvement in progression-free survival (PFS) and a positive overall survival (OS) trend.
The study’s primary endpoint of PFS was met, and further analyses are ongoing to assess other key measures such as OS, duration of response, and rates of minimal residual disease negativity. GSK’s team, led by Hesham Abdullah, is preparing to present detailed findings from the interim analysis soon.
Blenrep’s mechanism involves targeting the B-cell maturation antigen to deliver auristatin F, a cytotoxic agent, using technologies licensed from Seagen Inc. and BioWa Inc. This innovative approach aims to address the challenges of treating multiple myeloma, which is often considered manageable but not curable.
With the safety profiles consistent with previous data, GSK anticipates communicating these findings with health authorities for potential further action. For detailed safety information regarding Blenrep’s use in the European Union, stakeholders are referred to consult the European Medicines Agency (EMA) reference guide provided by GSK.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Read the full article here
-
Passive Income6 days ago
Are You Running Your Business, or Is Your Business Running You?
-
Side Hustles5 days ago
How to Be Unapologetically You and Why It Matters
-
Side Hustles6 days ago
How Your Body Language Can Help Win a Disagreement
-
Investing6 days ago
7 Marketing Strategies to Help Your Startup Grow and Scale
-
Side Hustles6 days ago
OpenAI Raises Record $6.6 Billion, Adds 50 Million New Users
-
Investing4 days ago
Nvidia CEO Jensen Huang: Demand For Blackwell AI Is Insane
-
Side Hustles4 days ago
Mark Zuckerberg Is Now Second Richest Person in the World
-
Side Hustles5 days ago
With AI Magicx, It’s Like Getting an Entire Creative Team in One Money-Saving AI Tool